Skip to main content
. 2021 Jun 18;69(7):1862–1866. doi: 10.4103/ijo.IJO_3156_20

Figure 1.

Figure 1

(a) Baseline SD-OCT image of neovascular AMD with SHRM (green asterisk) above RPE (b) Partial resolution of SHRM at 3 months after anti-VEGF therapy (c) Complete resolution of SHRM at 12-follow-up. (d) Baseline SD-OCT image of neovascular AMD with fibrovascular PED (green arrow) without SHRM (e) Partial resolution of SRF at 3 months after anti-VEGF therapy (f) Complete resolution of SRF with persistence of FVPED at 12-follow-up